Form 4: Caribou Biosciences CFO Granted Stock Options

Caribou Biosciences' Chief Financial Officer, Sriram Ryali, was granted options to purchase 300,000 shares of common stock.

Summary

• Sriram Ryali, the Chief Financial Officer of Caribou Biosciences, Inc., was granted an option to purchase 300,000 shares of the company's common stock.
• The option has an exercise price of $1.64 per share.
• The grant date was January 10, 2025.
• The options vest over time, with 25% vesting on January 2, 2026, and the remaining 75% vesting monthly over the following 36 months.
• The vesting is contingent upon Mr. Ryali's continued employment with Caribou Biosciences.

Sentiment

Score: 7

Explanation: The document reflects a standard executive compensation practice, which is generally viewed positively as it aligns management's interests with shareholders. There are no negative implications.

Positives

• The grant of stock options aligns the CFO's interests with those of the shareholders.
• The vesting schedule encourages long-term commitment from the CFO.

Risks

• The value of the options is dependent on the future performance of Caribou Biosciences' stock price.
• If the CFO leaves the company before the options fully vest, they may forfeit some or all of the options.

Industry Context

Stock option grants are a common form of compensation for executives in the biotechnology industry, aligning their interests with the long-term success of the company.

Comparison to Industry Standards

• Stock option grants are a standard practice for executive compensation in the biotech industry.
• The vesting schedule of 3.25 years is typical for such grants, designed to incentivize long-term performance.
• The exercise price of $1.64 is based on the current market price of the stock at the time of the grant.

Stakeholder Impact

• Shareholders may view the stock option grant positively as it incentivizes the CFO to increase the company's value.
• Employees may see this as a positive sign of the company's commitment to its leadership.

Key Dates

Keywords

stock options, executive compensation, insider trading, Caribou Biosciences, CRBU, Sriram Ryali, CFO